Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Colorectal Neoplasms 28Neoplasm Metastasis 4Gastrointestinal Stromal Tumors 4Colonic Neoplasms 4Carcinoma, Hepatocellular 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Rectal Neoplasms 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Bile Duct Neoplasms 2Adenocarcinoma 2Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Sarcoma 1Rhabdomyosarcoma 1Renal Insufficiency 1Physician Education 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Noonan Syndrome 6 1Metastatic Pancreatic Adenocarcinoma 1Melanoma 1Liver Neoplasms 1

Interventions

Temozolomide 3Capecitabine 3Everolimus 2Bevacizumab 2regorafenib 1motesanib diphosphate 1batifiban 1Sorafenib 1Oxaliplatin 1Octreotide 1Leucovorin 1Fluorouracil 1Fentanyl 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrinoma × regorafenib × Clear all
NCT02259725 2021-12-15

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

University of Southern California

Phase 2 Completed
3 enrolled 7 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡